SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
周小凡
Lv4
540 积分
2021-11-03 加入
最近求助
最近应助
互助留言
The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis
1小时前
已完结
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
1小时前
已完结
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
1小时前
已完结
Insulin Dosage Adjustments After Initiation of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes
1个月前
已完结
Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration
1个月前
已完结
An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation
1个月前
已完结
Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond
2个月前
已关闭
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A scandinavian cohort study
2个月前
已完结
中国2型糖尿病防治指南(2010年版)
2个月前
已完结
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
3个月前
已完结
没有进行任何应助
感谢
1小时前
速度真快
1小时前
点赞,速度真快
1小时前
点赞,速度真快,帮大忙了
1个月前
点赞,速度真快
1个月前
感谢,点赞
1个月前
感谢
2个月前
感谢,么么哒
2个月前
感谢,点赞
4个月前
感谢,点赞
5个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论